All manuscripts
Publications CAR T Cells

The Past, Present, and Future of Non-Viral CAR T Cells

Published Journal Frontiers in Immunology

Share
25 pages The Past, Present, and Future of Non-Viral CAR T Cells

Overview

This review weighs transposon systems, mRNA and nanocarriers against viral vectors for making CAR T cells, and finds the non-viral route cheaper and more flexible. The review also reports that two of ten patients in a piggyBac trial developed malignant CAR T cell tumors.

What this paper found

Non-viral gene transfer with Sleeping Beauty (SB) and piggyBac (PB) transposons, mRNA and nanocarriers is positioned as a cheaper, more flexible route to CAR T cell manufacturing than viral vectors. Transposon plasmids are estimated to cost 5 to 10 times less than the viral process, and SB integrates in a close-to-random pattern, whereas PB prefers sites near transcription start sites. A multicenter phase I/II trial (NCT03389035) treated 21 patients with B-ALL relapsed after allogeneic transplant using SB-engineered CARCIK-CD19 cells; acute GvHD was never observed. In the PB-based CARTELL study, two of 10 treated patients developed malignant CAR T cell tumors, so the authors recommend limiting transposase activity and integration number and monitoring clonality.

Note: The authors note that whether transposon-engineered CAR T cells show unexpected toxicities and comparable clinical outcomes remains to be seen in additional clinical studies.

We are encouraged by the prospect of non-viral vectors simplifying the CAR T supply chain, making it less expensive, safer, and efficacious. — Alex Moretti, Marianna Ponzo, Charles A. Nicolette, Irina Y. Tcherepanova, Andrea Biondi, Chiara F. Magnani, Frontiers in Immunology

Study details

Authors
Alex Moretti, Marianna Ponzo, Charles A. Nicolette, Irina Y. Tcherepanova, Andrea Biondi, Chiara F. Magnani
Institution
Tettamanti Research Center, Department of Pediatrics, University of Milano-Bicocca/Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM), Monza, Italy · CoImmune Inc., Durham, NC, United States · Department of Pediatrics, University of Milano - Bicocca, Milan, Italy · Clinica Pediatrica, University of Milano - Bicocca/Fondazione MBBM, Monza, Italy · Department of Medical Oncology and Hematology, University Hospital Zurich and University of Zurich, Zurich, Switzerland
Journal
Frontiers in Immunology
Year
2022
PMID / PMC
PMID: 35757746 · PMC
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy · Solid tumor

Explore related

Full citation

Moretti A, Ponzo M, Nicolette CA, Tcherepanova IY, Biondi A, Magnani CF. The Past, Present, and Future of Non-Viral CAR T Cells. Front Immunol. 2022;13:867013.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →